<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247686</url>
  </required_header>
  <id_info>
    <org_study_id>132-04</org_study_id>
    <nct_id>NCT03247686</nct_id>
  </id_info>
  <brief_title>A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome</brief_title>
  <acronym>RSLV-132</acronym>
  <official_title>A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Resolve Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Resolve Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will examine the role of circulating RNA complexed with autoantibodies and
      immune complexes and its role in activation of inflammatory pathways in patients with primary
      Sjogren's syndrome. The study will be conducted in a subset of Sjogren's patients who have
      elevated levels of autoantibodies and a pattern of elevated interferon-stimulated gene
      expression in blood cells. A number of biochemical and clinical parameters will be analyzed
      to determine the potential therapeutic utility of nuclease therapy in Sjogren's syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">January 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood cell gene expression</measure>
    <time_frame>Day 99</time_frame>
    <description>Interferon gene expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>European League Against Rheumatism (EULAR) Sj√∂gren's Syndrome Disease Activity Index (ESSDAI).</measure>
    <time_frame>Day 99</time_frame>
    <description>clinical disease activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSLV-132</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RSLV-132</intervention_name>
    <description>RNase Fc fusion protein</description>
    <arm_group_label>RSLV-132</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet 4 of 6 criteria of 2002 American-European Consensus Group (AECG) criteria for
             Primary Sjogren's Syndrome

          2. Presence of anti Ro autoantibodies

          3. Presence of interferon signature

        Exclusion Criteria:

          1. Use fo hydroxychloroquine within 30 days of baseline

          2. Use of cyclophosphamide within 180 days of baseline

          3. Use of oral corticosteroids greater than 10 mg/day

          4. Known IgG4-related disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Posada, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Resolve Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Posada, Ph.D.</last_name>
    <phone>208 727 7010</phone>
    <email>jp@resolvebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Edgbaston</state>
        <zip>B16 6TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Gosforth</state>
        <zip>NE3 3HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wan Fai Ng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

